Reducing immune-suppressing drugs after liver transplant with everolimus
Treatments studied
Part of Immune system & allergy clinical trials.
This study tests if adding everolimus can allow liver transplant recipients to safely reduce their usual immune-suppressing medicines. It aims to protect kidney function while preventing organ rejection.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old and have received your first liver transplant only.
- Your kidney function must be at least 30 ml/min (a blood test will check this).
- You must be currently taking tacrolimus (with or without other immune medicines).
- You need to have had vaccines for chickenpox, measles, hepatitis B, pneumonia, flu, shingles, and COVID-19 (or have immunity).
- You must not have certain liver diseases (like autoimmune hepatitis) or other conditions that prevent reducing immune medicines.
- You cannot have had severe rejection episodes after your transplant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing whether a combination of two drugs, everolimus and epoetin, can help liver transplant recipients gradually reduce their anti-rejection medicines. If successful, it may lead to long-term transplant tolerance with fewer side effects.
This research study tracks early signs of immune system changes in children who received a liver transplant 3–7 years ago and are doing well. By studying blood and liver samples, researchers hope to better understand how to prevent rejection and improve long-term transplant survival.
This trial tests whether older kidney transplant recipients can safely reduce their immunosuppression medications using a special monitoring tool called Trugraf. If you are over 55, have had a stable transplant, and want to possibly lower your medications, this study may be for you.
This trial tests if switching from a standard anti-rejection medicine to everolimus is safe and effective for liver transplant patients. It may help protect kidney function while preventing organ rejection.
This trial studies whether everolimus, a transplant medicine, can safely reduce the chance that liver cancer comes back after liver transplant. It compares how well the treatment works while carefully monitoring side effects and safety.
This trial studies whether everolimus can improve outcomes for people whose kidney transplant biopsy shows signs of a specific type of immune attack. It focuses on patients without certain antibodies and with particular biopsy findings, aiming to prevent rejection-related injury while balancing medication side effects.
Hear when a new Liver Transplant trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.